Trial Design: Open-label, international, multicentre window of opportunity phase II trial to evaluate the effects of short-term preoperative therapy with enzalutamide (alone or in combination with exemestane) in women with newly diagnosed invasive primary breast cancer. The study has two cohorts, an oestrogen receptor positive breast cancer cohort and an androgen receptor positive, triple-negative breast cancer cohort. Participants will receive treatment for 15 to 29 days, until either surgery or primary medical treatment (e.g. neoadjuvant chemotherapy) at the discretion of the treating physician. The effects of enzalutamide (alone or in combination with exemestane) will be assessed on tumour tissue specimens taken at baseline and on the last day of study treatment.
ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC. P. Schmid, P. Gomez-Padro, D. Wheatley et al. Annals of Oncology 32,5 S449-S450, September 01, 2021
ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer. Peter Schmid, Duncan A Wheatley, Alastair Mark Thompson et al. Journal of Clinical Oncology (2016) 34:15_suppl, TPS619-TPS619
Cancer Research UK website A trial looking at enzalutamide for early stage breast cancer (ARB)